首页> 外文期刊>Journal of Clinical Pathology >Receptor activator for nuclear factor κB expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis
【24h】

Receptor activator for nuclear factor κB expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis

机译:核因子κB表达的受体激活剂预示乳腺癌骨转移患者的预后较差,但内脏转移患者的预后较差

获取原文
获取原文并翻译 | 示例
       

摘要

Background It was recently reported that receptor activator for nuclear factor K B iigand (RANKL)Aeceptor activator for nuclear factor K B (RANK) pathway is critical for RANK-expressing cancer cells to home to bone and associates with disease progression of cancer. The present study was aimed to evaluate the effect of RANK on prognosis in breast cancer patients with bone metastasis and patients with visceral metastasis. Methods Immunohistochemical staining for RANK was carried out on paraffin-embedded primary tumour tissue sections from 102 patients with metastatic breast cancer. Survival analysis and Cox proportional hazards model were used to explore the prognostic value of RANK expression in breast cancer. Results The RANK expression rates were 47.1% in metastatic breast cancer. Patients with RANK expression showed significantly poor progression-free survival and disease-specific survival. Subgroup analysis demonstrated that the significant difference in prognosis completely resulted from the occurrence of bone metastasis. Multivariate analysis demonstrated that RANK expression was an independent predictor of bone metastasis-free survival and disease-specific survival in patients with bone metastasis. Conclusions RANK expression might be an independent predictor of poor prognosis in breast cancer patients with bone metastasis, and RANK expression does not associate with the prognosis in patients with visceral metastasis.
机译:背景技术最近报道,核因子κB配体(RANKL)的受体活化剂对核因子κB(RANK)途径的受体活化剂对于表达RANK的癌细胞回到骨骼并与癌症的疾病进展相关至关重要。本研究旨在评估RANK对乳腺癌骨转移和内脏转移患者预后的影响。方法对102例转移性乳腺癌患者石蜡包埋的原发肿瘤组织切片进行RANK的免疫组织化学染色。采用生存分析和Cox比例风险模型探讨RANK表达在乳腺癌中的预后价值。结果转移性乳腺癌的RANK表达率为47.1%。 RANK表达的患者显示无进展生存期和疾病特异性生存期明显差。亚组分析表明,预后的显着差异完全归因于骨转移的发生。多变量分析表明,RANK表达是骨转移患者无骨转移生存和疾病特异性生存的独立预测因子。结论RANK表达可能是乳腺癌骨转移患者预后不良的独立预测因子,而RANK表达与内脏转移患者的预后无关。

著录项

  • 来源
    《Journal of Clinical Pathology》 |2012年第1期|p.36-40|共5页
  • 作者单位

    Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China;

    Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China;

    Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China;

    Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China;

    Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China;

    Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China;

    Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China;

    Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, China;

    Department of Medical Oncology, The First Hospital of China Medical University, No.155, North Nanjing Street, Heping District, Shenyang 110001, China;

    Department of Medical Oncology, The First Hospital of China Medical University, No. 155, North Nanjing Street, Heping District, Shenyang 110001, China;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 01:35:12

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号